-
公开(公告)号：US20220324829A1
公开(公告)日：2022-10-13
申请号：US17224161
申请日：2021-04-07
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： YAN SHI , Peter Tai Wah Cheng , Ying Wang , Jun Shi , Shiwei Tao , Jun Li , Lawrence J. Kennedy , Robert F. Kaltenbach, III , Hao Zhang , James R. Corte
IPC: C07D401/04 , C07D403/04 , C07D249/06 , A61P35/00 , C07C249/06 , C07C403/04
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
-
公开(公告)号：US11008300B2
公开(公告)日：2021-05-18
申请号：US16744303
申请日：2020-01-16
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Yan Shi , Peter Tai Wah Cheng , Ying Wang , Jun Shi , Shiwei Tao , Jun Li , Lawrence J. Kennedy , Robert F. Kaltenbach, III , Hao Zhang , James R. Corte
IPC: C07D401/04 , C07D403/04 , C07D249/06 , A61P35/00 , A61P1/16 , A61P19/10 , A61P13/12 , A61P11/00 , C07C249/06 , C07C403/04
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
-
公开(公告)号：US11007180B2
公开(公告)日：2021-05-18
申请号：US16732387
申请日：2020-01-02
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Peter Tai Wah Cheng , Robert F. Kaltenbach, III , Jun Li , Jun Shi , Yan Shi , Shiwei Tao , Hao Zhang , Suresh Dhanusu , Kumaravel Selvakumar , Ramesh Babu Reddigunta , Steven J. Walker , Lawrence J. Kennedy , James R. Corte , Tianan Fang , Sutjano Jusuf
IPC: C07D401/04 , A61K31/4192 , C07D401/14 , C07D249/06 , A61K31/27 , A61K31/454 , A61K31/41 , C07C62/10
Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
-
公开(公告)号：US20210107897A1
公开(公告)日：2021-04-15
申请号：US17131718
申请日：2020-12-22
Applicant: Bristol-Myers Squibb Company
Inventor： Ke Chen , Joerg Deerberg , Dong Lin , Michael Dummeldinger , Bahar Inankur , Sergei Kolotuchin , Jun Li , Amanda J. Rogers , Victor W. Rosso , Eric M. Simmons , Maxime C.D. Soumeillant , Daniel S. Treitler , Jianji Wang , Bin Zheng , Michael J. Smith , Neil A. Strotman , Steven Tymonko , Tamas Benkovics
IPC: C07D403/12 , C07C211/09 , C07D237/24 , C07D249/08
Abstract: The invention relates to an improved process for synthesizing 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide of the formula: Compound I is currently in clinical trials for the treatment of auto-immune and auto-inflammatory diseases such as psoriasis.
-
公开(公告)号：US20210087178A1
公开(公告)日：2021-03-25
申请号：US16954325
申请日：2018-12-18
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Yan Shi , Ying Wang , Peter Tai Wah Cheng , Jun Li , Steven J. Walker
IPC: C07D403/14 , C07D401/14 , C07D401/04
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
-
Patent Agency Ranking
公开(公告)号：US10899745B2
公开(公告)日：2021-01-26
申请号：US16498442
申请日：2018-03-29
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Ke Chen , Joerg Deerberg , Dong Lin , Michael Dummeldinger , Bahar Inankur , Sergei Kolotuchin , Jun Li , Amanda J. Rogers , Victor W. Rosso , Eric M. Simmons , Daniel S. Treitler , Jianji Wang , Michael J. Smith , Tamas Benkovics
IPC: C07D403/12 , C07C211/09 , C07D237/24 , C07D249/08
Abstract: The invention relates to an improved process for synthesizing 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide of the formula: [INSERT CHEMICAL STRUCTURE HERE] Compound I is currently in clinical trials for the treatment of auto-immune and auto-inflammatory diseases such as psoriasis.
-
公开(公告)号：US10071078B2
公开(公告)日：2018-09-11
申请号：US15628104
申请日：2017-06-20
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Peter Tai Wah Cheng , Robert F. Kaltenbach, III , Jun Li , Jun Shi , Yan Shi , Shiwei Tao , Hao Zhang , Suresh Dhanusu , Kumaravel Selvakumar , Ramesh Babu Reddigunta , Steven J. Walker , Lawrence J. Kennedy , James R. Corte , Tianan Fang , Sutjano Jusuf
IPC: C07D401/04 , A61K31/4192 , A61K31/27 , A61K31/454 , C07D401/14 , C07D249/06 , A61K31/41 , C07C62/10
CPC classification number: A61K31/4192 , A61K31/27 , A61K31/41 , A61K31/454 , C07C62/10 , C07D249/06 , C07D401/04 , C07D401/14
Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
-
公开(公告)号：US20160060252A1
公开(公告)日：2016-03-03
申请号：US14784460
申请日：2014-04-14
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： William P. Gallagher , Prashant P. Deshpande , Jun Li , Kishta Katipally
IPC: C07D405/04 , C07D493/04
CPC classification number: C07D405/04 , C07D493/04
Abstract: The NRTI compound festinavir is made using 5-methyluridine as a starting material, followed by Claisen rearrangement.
Abstract translation: 使用5-甲基尿苷作为起始原料制备NRTI化合物festinavir，接着是Claisen重排。
-
公开(公告)号：US12195444B2
公开(公告)日：2025-01-14
申请号：US18321092
申请日：2023-05-22
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Yan Shi , Peter Tai Wah Cheng , Ying Wang , Jun Shi , Shiwei Tao , Jun Li , Lawrence J. Kennedy , Robert F. Kaltenbach, III , Hao Zhang , James R. Corte
IPC: C07D401/04 , A61P1/16 , A61P11/00 , A61P13/12 , A61P19/10 , A61P35/00 , C07C249/06 , C07C403/04 , C07D249/06 , C07D403/04
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
-
公开(公告)号：US20220249443A1
公开(公告)日：2022-08-11
申请号：US17718760
申请日：2022-04-12
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Peter Tai Wah Cheng , Robert F. Kaltenbach, III , Jun Li , Jun Shi , Yan Shi , Shiwei Tao , Hao Zhang , Suresh Dhanusu , Kumaravel Selvakumar , Ramesh Babu Reddigunta , Steven J. Walker , Lawrence J. Kennedy , James R. Corte , Tianan Fang , Sutjano Jusuf
IPC: A61K31/4192 , C07D401/14 , C07D249/06 , A61K31/27 , A61K31/454 , C07D401/04
Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
-
-
-
-
-
-
-
-
-
Search Results
36
records
(took 0.029 seconds)
